Academic Journal
Mismatch repair and microsatellite instability testing for Immune Checkpoint Inhibitor Therapy: ASCO endorsement of College of American Pathologists Guideline
| Τίτλος: | Mismatch repair and microsatellite instability testing for Immune Checkpoint Inhibitor Therapy: ASCO endorsement of College of American Pathologists Guideline |
|---|---|
| Συγγραφείς: | Vikas, Praveen, Messersmith, Hans, Compton, Carolyn, Sholl, Lynette, Broaddus, Russell R., Davis, Anjee, Estevez-Diz, Maria, Garje, Rohan, Konstantinopoulos, Panagiotis A., Leiser, Aliza, Mills, Anne M., Norquist, Barbara, Overman, Michael J., Sohal, Davendra, Turkington, Richard C., Johnson, Tyler |
| Πηγή: | Vikas, P, Messersmith, H, Compton, C, Sholl, L, Broaddus, R R, Davis, A, Estevez-Diz, M, Garje, R, Konstantinopoulos, P A, Leiser, A, Mills, A M, Norquist, B, Overman, M J, Sohal, D, Turkington, R C & Johnson, T 2023, 'Mismatch repair and microsatellite instability testing for Immune Checkpoint Inhibitor Therapy: ASCO endorsement of College of American Pathologists Guideline', Journal of Clinical Oncology, vol. 41, no. 10, pp. 1943-1948. https://doi.org/10.1200/jco.22.02462 |
| Έτος έκδοσης: | 2023 |
| Συλλογή: | Queen's University Belfast: Research Portal |
| Θεματικοί όροι: | Cancer Research, Oncology, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being |
| Περιγραφή: | The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. The CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations. The ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses . Within the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician.Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines. |
| Τύπος εγγράφου: | article in journal/newspaper |
| Περιγραφή αρχείου: | application/pdf |
| Γλώσσα: | English |
| ISSN: | 0732-183X 1527-7755 |
| Relation: | info:eu-repo/semantics/altIdentifier/pissn/0732-183X; info:eu-repo/semantics/altIdentifier/eissn/1527-7755 |
| DOI: | 10.1200/jco.22.02462 |
| Διαθεσιμότητα: | https://pure.qub.ac.uk/en/publications/27e83e85-c2f2-4bab-a401-36fec578ee00 https://doi.org/10.1200/jco.22.02462 https://pureadmin.qub.ac.uk/ws/files/548274535/MMREndorsementDRAFT2022_09_14_1_.pdf https://www.scopus.com/pages/publications/85149831285 |
| Rights: | info:eu-repo/semantics/openAccess |
| Αριθμός Καταχώρησης: | edsbas.C78F37EC |
| Βάση Δεδομένων: | BASE |
| ISSN: | 0732183X 15277755 |
|---|---|
| DOI: | 10.1200/jco.22.02462 |